Tomotherapy: a new concept for the delivery of dynamic conformal radiotherapy

Toxicity report of a phase 1/2 dose-escalation study in patients with inoperable, locally advanced nonsmall cell lung cancer with helical tomotherapy and concurrent chemotherapy

BACKGROUND

The objective of the current study was to evaluate the feasibility and toxicity of radiation dose escalation with concurrent chemotherapy using helical tomotherapy (HT) in patients with inoperable, locally advanced, stage III nonsmall cell lung cancer (LANSCLC) (grading determined according to the American Joint Committee on Cancer 6th edition grading system).

METHODS

This phase 1/2 study was designed to determine the maximum tolerated dose (MTD) of radiotherapy in patients with LANSCLC administered concurrently with docetaxel and cisplatin. Radiotherapy was delivered using HT. A dose per fraction escalation was applied starting at 2 grays (Gy), with an increase of 6% per dose cohort (DC). The Radiation Therapy Oncology Group acute radiation morbidity score was used to monitor pulmonary, esophageal, and cardiac toxicity.

RESULTS

Dose escalation was performed in 34 patients over 5 DCs to a dose per fraction of 2.48 Gy. No differences were observed in acute toxicity between the different DCs. However, a significant increase in late lung toxicity in DC IV, which received a fraction size of 2.36 Gy, necessitated a halt in further dose escalation with the MTD defined as 2.24 Gy per fraction. The overall incidence of acute grade > or =3 esophageal and pulmonary toxicity was 24% and 3%, respectively (grading determined according to the Radiation Therapy Oncology Group-European Organisation for Research and Treatment of Cancer toxicity scoring system). The overall incidence of late lung toxicity was 21%, but the incidence was an acceptable 13% in DCs I, II, and III. The local response rate was 61% on computed tomography images.

CONCLUSIONS

The use of HT to 67.2 Gy with concurrent cisplatin/docetaxel was feasible and resulted in acceptable toxicity. A full phase 2 study has been initiated to establish the true local response rate at the MTD of 2.24 Gy per fraction.

The number of beams in IMRT--theoretical investigations and implications for single-arc IMRT

The first purpose of this paper is to shed some new light on the old question of selecting the number of beams in intensity-modulated radiation therapy (IMRT). The second purpose is to illuminate the related issue of discrete static beam angles versus rotational techniques, which has recently re-surfaced due to the advancement of volumetric modulated arc therapy (VMAT). A specific objective is to find analytical expressions that allow one to address the points raised above. To make the problem mathematically tractable, it is assumed that the depth dose is flat and that the lateral dose profile can be approximated by polynomials, specifically Chebyshev polynomials of the first kind, of finite degree. The application of methods known from image reconstruction then allows one to answer the first question above as follows: the required number of beams is determined by the maximum degree of the polynomials used in the approximation of the beam profiles, which is a measure of the dose variability. There is nothing to be gained by using more beams. In realistic cases, in which the variability of the lateral dose profile is restricted in several ways, the required number of beams is of the order of 10-20. The consequence of delivering the beams with a 'leaf sweep' technique during continuous rotation of the gantry, as in VMAT, is also derived in an analytical form. The main effect is that the beams fan out, but the effect near the axis of rotation is small. This result can serve as a theoretical justification of VMAT. Overall the analytical derivations in this paper, albeit based on strong simplifications, provide new insights into, and a deeper understanding of, the beam angle problem in IMRT. The decomposition of the beam profiles into well-behaved and easily deliverable smooth functions, such as Chebyshev polynomials, could be of general interest in IMRT treatment planning.

New developments in arc radiation therapy: a review

Arc therapies have gained widespread clinical interest in radiation oncology over the past decade. Arc therapies have several potential advantages over standard techniques such as intensity-modulated radiation therapy, with implications for patients, administrators, and oncologists. This review focuses on the rationale for arc therapy, descriptions of the modern arc techniques that are currently clinically available, and highlights some distinguishing features of arc therapies, such as dose distributions, treatment times, and imaging capabilities. Arc therapies are exciting examples of progress in radiotherapy through technological innovation, aimed at ultimately improving the therapeutic ratio for patients receiving radiation.

Simultaneous integrated boost in breast conserving treatment of breast cancer: a dosimetric comparison of helical tomotherapy and three-dimensional conformal radiotherapy

BACKGROUND AND PURPOSE

To evaluate the dosimetry of helical tomotherapy (HT) and three-dimensional conformal radiotherapy (3D-CRT) in breast cancer patients undergoing whole breast radiation with simultaneous integrated boost (SIB) of the tumor bed.

MATERIAL AND METHODS

Thirteen patients with breast cancer treated by lumpectomy and requiring whole breast radiotherapy with tumor bed boost were planned using both HT and 3D-CRT using the field-in-field technique. The whole breast and tumor bed were prescribed 50.68 Gy and 64.4 Gy, respectively, in 28 fractions. Dosimetries for both techniques were compared.

RESULTS

Coverage of the whole breast was adequate with both techniques (V(95%)=96.22% vs. 96.25%, with HT and 3D-CRT, respectively; p=0.64). Adequate tumor bed coverage was also achieved, although it was significantly lower with HT (V(95%)=97.18% vs. 99.72%; p<0.001). Overdose of the breast volume outside the tumor bed was significantly lower with HT (V(54.23 Gy)=12.47% vs. 30.83%; p<0.001). Ipsilateral lung V(20 Gy) (6.34% vs. 10.17%; p<0.001), V(5 Gy) (16.54% vs. 18.53%; p<0.05) and mean dose (4.05 Gy vs. 6.36 Gy; p<0.001) were significantly lower with HT. In patients with left-sided tumors, heart V(30 Gy) (0.03% vs. 1.14%; p<0.05) and mean dose (1.35 Gy vs. 2.22 Gy; p<0.01) were significantly lower with HT, but not V(5 Gy). Contralateral breast V(5 Gy) (0.27% vs. 0.00%; p<0.01) and maximum dose were significantly increased with HT.

CONCLUSIONS

In breast cancer treated with SIB, both HT and 3D-CRT provided adequate target volume coverage and low heart doses. Tumor bed coverage was slightly lower with HT, but HT avoided unnecessary breast overdosage while improving ipsilateral lung dosimetry.

The European Society of Therapeutic Radiology and Oncology-European Institute of Radiotherapy (ESTRO-EIR) report on 3D CT-based in-room image guidance systems: a practical and technical review and guide

The past decade has provided many technological advances in radiotherapy. The European Institute of Radiotherapy (EIR) was established by the European Society of Therapeutic Radiology and Oncology (ESTRO) to provide current consensus statement with evidence-based and pragmatic guidelines on topics of practical relevance for radiation oncology. This report focuses primarily on 3D CT-based in-room image guidance (3DCT-IGRT) systems. It will provide an overview and current standing of 3DCT-IGRT systems addressing the rationale, objectives, principles, applications, and process pathways, both clinical and technical for treatment delivery and quality assurance. These are reviewed for four categories of solutions; kV CT and kV CBCT (cone-beam CT) as well as MV CT and MV CBCT. It will also provide a framework and checklist to consider the capability and functionality of these systems as well as the resources needed for implementation. Two different but typical clinical cases (tonsillar and prostate cancer) using 3DCT-IGRT are illustrated with workflow processes via feedback questionnaires from several large clinical centres currently utilizing these systems. The feedback from these clinical centres demonstrates a wide variability based on local practices. This report whilst comprehensive is not exhaustive as this area of development remains a very active field for research and development. However, it should serve as a practical guide and framework for all professional groups within the field, focussed on clinicians, physicists and radiation therapy technologists interested in IGRT.

Helical tomotherapy in the radiotherapy treatment of Hodgkin's disease - a feasibility study

Radiation therapy for advanced Hodgkin's disease often requires large fields and may result in significant exposure of normal tissues to ionizing radiation. In long-term survivors, this may increase the risk for late toxicity including secondary malignancies. 3DCRT has been successfully used to treat this disease but treatment delivery is often complex requiring matching of photon with electron beams, utilization of field-in-field techniques and of partial transmission blocks. HT is an arc-rotational intensity modulated radiation therapy technique proven to achieve superior target dose conformality and sharp dose gradients around critical normal tissues. HT however, has also been associated with higher volumes of low dose regions in normal tissues and therefore, higher integral dose. The present study was undertaken to compare the dosimetry of 3DCRT to HT in a pediatric patient with advanced HD. Clinical target volume (CTV) included bilateral lower cervical and supraclavicular areas, mediastinum, bilateral hili, left axilla and bilateral diaphragmatic lymph nodes. The planning target volume (PTV) was derived by circumferentially expanding the CTV by 1 cm. Whole lung and heart irradiation was also planned due to bilateral pleural and pericardial effusions. The prescribed radiation dose was 21 Gy to the PTV and 10.5 Gy to the whole lung and heart. Target coverage was comparable for both plans. The minimum, maximum and mean PTV doses were 18.61 Gy, 22.45 Gy and 21.52 Gy with 3DCRT and 19.85 Gy, 22.36 Gy and 21.39 Gy with HT, respectively. HT decreased mean normal tissue dose by 21.6% and 20.07% for right and left breast, 20.40% for lung, 30.78% for heart and 22.74% for the thyroid gland. Integral dose also decreased with HT by 46.50%. HT results in significant dosimetric gain related to normal tissue sparing compared to 3DCRT. Further studies are warranted to evaluate clinical applications of HT in patients with HD.

Commissioning experience and quality assurance of helical tomotherapy machines

A helical tomotherapy machine combines a straight 6 MV linear accelerator mounted on a ring gantry with CT technology for image-guided intensity-modulated radiation therapy (IMRT) treatment. A fan beam created by the collimator and jaws produces a maximum of 40 × 5 cm² field size at the isocenter. The gantry and hence the fan beam rotates at a constant speed while the couch moves linearly into the gantry bore, thus producing a helical delivery. The beam is modulated by a 64-leaf binary multileaf collimator (MLC), which enables IMRT treatment. The linac can be operated at a lower voltage (3.5 MV) and dose rate to produce megavoltage CT images, which are used for image-guided patient setup. We have installed two such units since 2004 and treated more than 2000 patients. The machine comes “precommissioned” from the manufacturer, and the beam characteristics and IMRT plans on phantom are measured and compared with manufacturer's data after acceptance tests are performed on site. Our experience with commissioning the machines and periodic quality assurance with tolerance limits for optimal performance are described.

Toxicity and outcome results of a class solution with moderately hypofractionated radiotherapy in inoperable Stage III non-small cell lung cancer using helical tomotherapy

PURPOSE

To prospectively assess the feasibility, toxicity, and local control of a class solution protocol of moderately hypofractionated tomotherapy in Stage III, inoperable, locally advanced non-small-cell lung cancer patients.

METHODS AND MATERIALS

Eligible patients were treated according to a uniform class solution (70.5 Gy in 30 fractions) with fixed constraints and priorities using helical tomotherapy. Toxicity monitoring was performed using the Radiation Therapy Oncology Group criteria and the National Cancer Institute Common Terminology Criteria and Adverse Events (CTCAE) version 3.0. Pulmonary function tests were performed at the start and repeated at 3 months after treatment.

RESULTS

Our class solution resulted in a deliverable plan in all 40 consecutive patients. Acute Grade 3 lung toxicity was seen in 10% of patients. Two patients died during acute follow-up with pulmonary toxicity. Correlations were found between changes in pulmonary function test results and mean lung dose or the lung volume receiving 20 Gy (V(20)). The correlation was strongest for lung diffusion capacity for carbon monoxide. A V(20) of >27% and >32% were predictive for Grades 2 and 3 acute lung toxicity respectively (p < 0.05). Late Grade 3 toxicity was exclusively pulmonary, with an incidence of 16%. Overall Grade 3 lung toxicity correlated with a mean lung dose of >18 Gy and a median lung dose of >5 Gy (p < 0.05). Median survival was 17 months, and the 1-year and 2-year local progression-free survivals were 66% and 50%, respectively.

CONCLUSION

The current class solution using moderately hypofractionated helical tomotherapy in patients with locally advanced non-small-cell lung cancer is feasible. Toxicity was acceptable and in line with other reports on intensity-modulated radiotherapy. The local progression-free survival was encouraging considering the unselected population.

Evolution of surface-based deformable image registration for adaptive radiotherapy of non-small cell lung cancer (NSCLC)

BACKGROUND

To evaluate the performance of surface-based deformable image registration (DR) for adaptive radiotherapy of non-small cell lung cancer (NSCLC).

METHODS

Based on 13 patients with locally advanced NSCLC, CT images acquired at treatment planning, midway and the end of the radio- (n = 1) or radiochemotherapy (n = 12) course were used for evaluation of DR. All CT images were manually [gross tumor volume (GTV)] and automatically [organs-at-risk (OAR) lung, spinal cord, vertebral spine, trachea, aorta, outline] segmented. Contours were transformed into 3D meshes using the Pinnacle treatment planning system and corresponding mesh points defined control points for DR with interpolation within the structures. Using these deformation maps, follow-up CT images were transformed into the planning images and compared with the original planning CT images.

RESULTS

A progressive tumor shrinkage was observed with median GTV volumes of 170 cm(3) (range 42 cm(3) - 353 cm(3)), 124 cm(3) (19 cm(3) - 325 cm(3)) and 100 cm(3) (10 cm(3) - 270 cm(3)) at treatment planning, mid-way and at the end of treatment. Without DR, correlation coefficients (CC) were 0.76 +/- 0.11 and 0.74 +/- 0.10 for comparison of the planning CT and the CT images acquired mid-way and at the end of treatment, respectively; DR significantly improved the CC to 0.88 +/- 0.03 and 0.86 +/- 0.05 (p = 0.001), respectively. With manual landmark registration as reference, DR reduced uncertainties on the GTV surface from 11.8 mm +/- 5.1 mm to 2.9 mm +/- 1.2 mm. Regarding the carina and intrapulmonary vessel bifurcations, DR reduced uncertainties by about 40% with residual errors of 4 mm to 6 mm on average. Severe deformation artefacts were observed in patients with resolving atelectasis and pleural effusion, in one patient, where the tumor was located around large bronchi and separate segmentation of the GTV and OARs was not possible, and in one patient, where no clear shrinkage but more a decay of the tumor was observed.

DISCUSSION

The surface-based DR performed accurately for the majority of the patients with locally advanced NSCLC. However, morphological response patterns were identified, where results of the surface-based DR are uncertain.

Accelerated ray tracing for radiotherapy dose calculations on a GPU

PURPOSE

The graphical processing unit (GPU) on modern graphics cards offers the possibility of accelerating arithmetically intensive tasks. By splitting the work into a large number of independent jobs, order-of-magnitude speedups are reported. In this article, the possible speedup of PLATO's ray tracing algorithm for dose calculations using a GPU is investigated.

METHODS

A GPU version of the ray tracing algorithm was implemented using NVIDIA's CUDA, which extends the standard C language with functionality to program graphics cards. The developed algorithm was compared based on the accuracy and speed to a multithreaded version of the PLATO ray tracing algorithm. This comparison was performed for three test geometries, a phantom and two radiotherapy planning CT datasets (a pelvic and a head-and-neck case). For each geometry, four different source positions were evaluated. In addition to this, for the head-and-neck case also a vertex field was evaluated.

RESULTS

The GPU algorithm was proven to be more accurate than the PLATO algorithm by elimination of the look-up table for z indices that introduces discretization errors in the reference algorithm. Speedups for ray tracing were found to be in the range of 2.1-10.1, relative to the multithreaded PLATO algorithm running four threads. For dose calculations the speedup measured was in the range of 1.5-6.2. For the speedup of both the ray tracing and the dose calculation, a strong dependency on the tested geometry was found. This dependency is related to the fraction of air within the patient's bounding box resulting in idle threads.

CONCLUSIONS

With the use of a GPU, ray tracing for dose calculations can be performed accurately in considerably less time. Ray tracing was accelerated, on average, with a factor of 6 for the evaluated cases. Dose calculation for a single beam can typically be carried out in 0.6-0.9 s for clinically realistic datasets. These findings can be used in conventional planning to enable (nearly) real-time dose calculations. Also the importance for treatment optimization techniques is evident.

Dynamic jaws and dynamic couch in helical tomotherapy

PURPOSE

To investigate the next generation of helical tomotherapy delivery with dynamic jaw and dynamic couch movements.

METHODS AND MATERIALS

The new technique of dynamic jaw and dynamic couch movements is described, and a comparative planning study is performed. Ten nasopharyngeal cancer patients with skull base infiltration were chosen for this comparison of longitudinal dose profiles using regular tomotherapy delivery, running-start-stop treatment, and dynamic jaw and dynamic couch delivery. A multifocal simultaneous integrated boost concept was used (70.4Gy to the primary tumor and involved lymph nodes; 57.4Gy to the bilateral cervical lymphatic drainage pathways, 32 fractions). Target coverage, conformity, homogeneity, sparing of organs at risk, integral dose, and radiation delivery time were evaluated.

RESULTS

Mean parotid dose for all different deliveries was between 24.8 and 26.1Gy, without significant differences. The mean integral dose was lowered by 6.3% by using the dynamic technique, in comparison with a 2.5-cm-field width for regular delivery and 16.7% with 5-cm-field width for regular delivery. Dynamic jaw and couch movements reduced the calculated radiation time by 66% of the time required with regular 2.5-cm-field width delivery (199 sec vs. 595 sec, p < 0.001).

CONCLUSIONS

The current delivery mode of helical tomotherapy produces dose distributions with conformal avoidance of parotid glands, brain stem, and spinal cord. The new technology with dynamic jaw and couch movements improves the plan quality by reducing the dose penumbra and thereby reducing the integral dose. In addition, radiation time is reduced by 66% of the regular delivery time.

Concurrent chemoradiotherapy with helical tomotherapy for oropharyngeal cancer: a preliminary result

PURPOSE

To review the experience with and evaluate the treatment plan for helical tomotherapy for the treatment of oropharyngeal cancer.

METHODS AND MATERIALS

Between November 1, 2006 and January 31, 2009, 10 histologically confirmed oropharyngeal cancer patients were enrolled. All patients received definitive concurrent chemoradiation with helical tomotherapy. The prescription dose to the gross tumor planning target volume, the high-risk subclinical area, and the low-risk subclinical area was 70 Gy, 63 Gy, and 56 Gy, respectively. During radiotherapy, all patients were treated with cisplatin, 30 mg/m(2), plus 5-fluorouracil (425 mg/m(2))/leucovorin (30 mg/m(2)) intravenously weekly. Toxicity of treatment was scored according to the Common Terminology Criteria for Adverse Events, version 3.0. Several parameters, including maximal or median dose to critical organs, uniformity index, and conformal index, were evaluated from dose-volume histograms.

RESULTS

The mean survival was 18 months (range, 7-22 months). The actuarial overall survival, disease-free survival, locoregional control, and distant metastasis-free rates at 18 months were 67%, 70%, 80%, and 100%, respectively. The average for uniformity index and conformal index was 1.05 and 1.26, respectively. The mean of median dose for right side and left side parotid glands was 23.5 and 23.9 Gy, respectively. No Grade 3 toxicity for dermatitis and body weight loss and only one instance of Grade 3 mucositis were noted.

CONCLUSION

Helical tomotherapy achieved encouraging clinical outcomes in patients with oropharyngeal carcinoma. Treatment toxicity was acceptable, even in the setting of concurrent chemotherapy. Long-term follow-up is needed to confirm these preliminary findings.

A generalized inverse planning tool for volumetric-modulated arc therapy

The recent development in linear accelerator control systems, named volumetric-modulated arc therapy (VMAT), has generated significant interest in arc-based intensity-modulated radiation therapy (IMRT). The VMAT delivery technique features simultaneous changes in dose rate, gantry angle and gantry rotation speed as well as multi-leaf collimator (MLC) leaf positions while radiation is on. In this paper, we describe a generalized VMAT planning tool that is designed to take full advantage of the capabilities of the new linac control systems. The algorithm incorporates all of the MLC delivery constraints such as restrictions on MLC leaf interdigitation and the MLC leaf velocity constraints. A key feature of the algorithm is that it is able to plan for both single- and multiple-arc deliveries. Compared to conventional step-and-shoot IMRT plans, our VMAT plans created using this tool can achieve similar or better plan quality with less MU and better delivery efficiency. The accuracy of the obtained VMAT plans is also demonstrated through plan verifications performed on an Elekta Synergy linear accelerator equipped with a conventional MLC of 1 cm leaf width using a PreciseBeam VMAT linac control system.

Treatment planning of epithelial ovarian cancers using helical tomotherapy

Whole abdomen radiotherapy (WAR) for epithelial ovarian cancer, though effective, has been used sparingly due to inadequate target coverage and poor sparing of organs at risk (OAR) leading to significantly higher toxicities. Newer radiation techniques have shown potential for significant improvement in the therapeutic ratio. The purpose of this study was to evaluate helical tomotherapy (HT) for WAR. The objective parameters were to obtain uniform and adequate target coverage with maximum OAR sparing. HT plans were generated for five patients with field width of 5.0/2.5 cm, modulation factor of 3.5/3.0, and a pitch of 0.3. A dose of 25 Gy in 25 fractions was prescribed to the abdomen with a simultaneous boost of 45 Gy in 25 fractions to the pelvis. Dose‐volume parameters and various indices were analyzed and compared. Mean volume (standard deviation) of abdominal and pelvic PTV (planning target volume) was 6630 ± 450 cm3 and 1235 ± 98 cm3, respectively. Mean length of PTV in cranio‐caudal direction was 41 ± 4 cm. Volume receiving 95% and 107% of the prescription dose (V95% and V107%) was 95.6 ± 2.7% and 2.6 ± 0.5% for abdominal‐PTV, and 95.7±2.4% and 0% for pelvic‐PTV, respectively. Homogeneity and conformity indices were 17.5±1.7,1.2±0.03 for abdominal PTV, and 5.2±0.7,1.1±0.02 for pelvic‐PTV, respectively. Median dose received by the kidneys, liver and bone marrow was 9.6±1.2Gy,17±2.7Gy and 22±1.4Gy, respectively. HT achieves an excellent coverage of WAR target with simultaneous pelvic boost and better organ (kidneys and liver) sparing. HT for WAR has the potential as consolidative therapy; this is being evaluated further in a phase II cohort study in epithelial ovarian cancers.

PACS number: 87.53 Kn, 87.55. D‐, 87.55.dk.

Comparing planning time, delivery time and plan quality for IMRT, RapidArc and Tomotherapy

The purpose of this study is to examine plan quality, treatment planning time, and estimated treatment delivery time for 5- and 9-field sliding window IMRT, single and dual arc RapidArc, and tomotherapy. For four phantoms, 5- and 9-field IMRT, single and dual arc RapidArc and tomotherapy plans were created. Plans were evaluated based on the ability to meet dose-volume constraints, dose homogeneity index, radiation conformity index, planning time, estimated delivery time, integral dose, and volume receiving more than 2 and 5 Gy. For all of the phantoms, tomotherapy was able to meet the most optimization criteria during planning (50% for P1, 67% for P2, 0% for P3, and 50% for P4). RapidArc met less of the optimization criteria (25% for P1, 17% for P2, 0% for P3, and 0% for P4), while IMRT was never able to meet any of the constraints. In addition, tomotherapy plans were able to produce the most homogeneous dose. Tomotherapy plans had longer planning time, longer estimated treatment times, lower conformity index, and higher integral dose. Tomotherapy plans can produce plans of higher quality and have the capability to conform dose distributions better than IMRT or RapidArc in the axial plane, but exhibit increased dose superior and inferior to the target volume. RapidArc, however, is capable of producing better plans than IMRT for the test cases examined in this study.

18F-FDG PET/CT for image-guided and intensity-modulated radiotherapy

Advances in technology have allowed extremely precise control of radiation dose delivery and localization within a patient. The ability to confidently delineate target tumor boundaries, however, has lagged behind. (18)F-FDG PET/CT, with its ability to distinguish metabolically active disease from normal tissue, may provide a partial solution to this problem. Here we review the current applications of (18)F-FDG PET/CT in a variety of disease sites, including non-small cell lung cancer, head and neck cancer, and pancreatic adenocarcinoma. This review focuses on the use of (18)F-FDG PET/CT to aid in planning radiotherapy and the associated benefits and challenges. We also briefly consider novel radiopharmaceuticals that are beginning to be used in the context of radiotherapy planning.

Early CT findings of tomotherapy-induced radiation pneumonitis after treatment of lung malignancy

OBJECTIVE

The objective of our study was to evaluate the early CT findings of tomotherapy-induced radiation pneumonitis.

MATERIALS AND METHODS

Tomotherapy was performed during the study period in 31 patients with peripheral pulmonary malignancies, 25 of whom underwent follow-up CT within the first 3 months after tomotherapy. These 25 patients, with a total of 77 target lesions, were enrolled for the analysis. We evaluated pulmonary toxicity by the Common Toxicity Criteria for Adverse Events (CTCAE) method and retrospectively analyzed the CT findings of radiation pneumonitis, focusing on the appearance (attenuation, shape, degree of fibrosis) and location (concentric vs eccentric, centrifugal vs centripetal) of radiation pneumonitis relative to the target lesions.

RESULTS

Radiation pneumonitis developed around 34 target lesions (34/77, 44%) in 13 patients (13/25, 52%) during the first 3 months after tomotherapy. Five patients needed steroid therapy (CTCAE grade 2, 5/25 [20%]) and the remaining eight patients required no additional treatment (CTCAE grade 0 or 1, 20/25 [80%]). In appearance, the common CT findings were irregular shape (18/34), ground-glass attenuation (19/34), and no or minimal fibrosis (33/34). The location of the radiation pneumonitis was eccentric (22/34) and centrifugal (19/34) relative to the target lesions.

CONCLUSION

Radiation pneumonitis commonly developed with minimal clinical findings within 3 months after tomotherapy. The CT findings were nonspecific: focal, irregular-shaped ground-glass opacities with minimal fibrosis. However, the location of the radiation pneumonitis tended not to correspond to the planned target volume and had a centrifugal distribution. In addition, the immediate area around the target tended to be spared.

Fast neutron and proton therapy sources

Neutrons from the reactions of protons or deuterons of energies between 35 and 70 MeV on beryllium are most suitable for therapy because of the high yield and good penetration. Lower energy sources are used for limited applications. Proton therapy is conducted mainly in two energy ranges, viz. 60–75 MeV (exclusively for the treatment of eye lesions) and ≥200 MeV for general applications. Characterisation of both neutron and proton therapy beams in terms of spectral fluence is important for accurate determination of dosimetry parameters, for interpreting biological effects, for intercomparison purposes and to perform accurate radiation transport calculations.

Preliminary experience of helical tomotherapy for locally advanced pancreatic cancer

Radiotherapy for locally advanced pancreatic cancer is technically difficult and frequently associated with high-grade digestive toxicity. Helical tomotherapy (HT) is a new irradiation modality that combines megavoltage computed tomography imaging for patient positioning with intensity-modulated fan-beam radiotherapy. Its recent availability opens new fields of exploration for pancreatic radiotherapy as a result of its ability to tailor very well-defined dose distributions around the target volumes. Here, we report the use of HT in two patients with locally advanced pancreatic cancer. Doses to the bowel, kidneys and liver were reduced significantly, which allowed for excellent treatment tolerance without any high-grade adverse effects in either patient.

Volumetric response analysis during chemoradiation as predictive tool for optimizing treatment strategy in locally advanced unresectable NSCLC

PURPOSE

To study the feasibility of measuring volumetric changes in the primary tumor on megavoltage-computed tomography (MVCT) during chemoradiation and to examine the correlation with local response.

PATIENTS AND METHODS

Fifteen consecutive patients with stage III, inoperable, locally advanced non-small cell lung cancer (NSCLC) were treated in a prospective dose escalation study protocol of concurrent chemoradiation. They were monitored for acute toxicity and evaluated with daily MVCT imaging. The volumetric changes were fitted to a negative exponential resulting in a regression coefficient (RC). Local response evaluation was done with positron emission tomography using the radio-labeled glucose analogue F18 fluorodeoxyglucose (FDG-PET).

RESULTS

The mean volume decrease (+/-standard deviation) was 73% (+/-18%). With a mean treatment time of 42days this treatment schedule resulted in a mean decrease of 1.74%/day. Of the 13 evaluable patients seven developed a metabolic complete remission (MCR). The mean RC of the patients with MCR is 0.050 versus a mean RC of 0.023 in non-responders (p=0.0074). Using a proposed cut-off value for the RC of 0.03 80% of the non-responders will be detected correctly while misclassifying 16.4% of patients who will eventually achieve an MCR. The total cumulative percentage of esophageal grade 3 or more toxicity was 46.7%.

CONCLUSION

The RC derived from volumetric analysis of daily MVCT is prognostic and predictive for local response in patients treated with chemoradiation for a locally advanced NSCLC. Because this treatment schedule is toxic in nearly half of the patient population, MVCT is a tool in the implementation of patient-individualized treatment strategies.

Surface dose in the treatment of breast cancer with helical tomotherapy

PURPOSE

Investigation of the effects of breathing motion- and misregistration-induced errors on the superficial dose in the treatment of breast cancer using helical tomotherapy (HT).

MATERIAL AND METHODS

Surface dose measurements were performed with thermoluminescence dosimetry (TLD). Two treatment plans with different planning target volume (PTV) definitions of the left breast were used: PTVskin had its ventral border exactly on skin level, while PTVair included also a 10-mm extension ventral to the PTVskin. With a thoracic static phantom, misregistration errors in an HT were simulated. A dynamic phantom was used to simulate a breathing patient during HT. Surface doses of breast cancer patients were measured both for an HT (179 points) and a conventional three-dimensional conformal treatment (70 points).

RESULTS

In the static phantom misregistration setup, dose deviations of -31.9% for PTVskin to +35.4% for PTVair could be observed. The dynamic phantom measurements resulted in surface dose deviations from those in a static position between 0.8% and 3.8% without a significant difference for the PTV definitions. The measured surface doses on patients averaged (mean +/- standard deviation) 1.65 +/- 0.13 Gy for the HT and 1.42 +/- 0.11 Gy for the three-dimensional conformal treatment.

CONCLUSION

HT enables a homogeneous and reproducible surface dose with small dose deviations in the treatment of breast cancer. HT is a feasible method to treat breast cancer under free shallow breathing of the patient using a treatment plan with a ventral PTV border on the skin level.

An approach to multiobjective optimization of rotational therapy

Multiobjective optimization is used in radiotherapy, especially IMRT, to generate treatment plans which meet different objectives to varying extents. Trade-off surfaces can be constructed representing the gains and losses of different objectives when switching from one plan to another, and the planner can interactively explore different treatment possibilities without the need for reoptimization. In this work a method for the multiobjective optimization of rotational therapy is introduced. The proposed method is applied slice per slice and uses the geometry of the slice directly to construct several arcs, each conformally irradiating the tumor and blocking a number (0,1,2,...) of different organs at risk present in the treatment. The blocked arc dose distributions so obtained are quite inhomogeneous in the target. An algorithm, based on the iterative reconstruction of images from projections, has been developed to compensate for this inhomogeneity, leading to compensated blocked arcs which deliver more uniform target doses but still block critical structures. Different treatments can be obtained as linear combinations of these arcs, each involving different trade-offs among the objectives involved. The compensatory algorithm substantially improves the target dose uniformity of blocked arcs at the cost of slightly increasing the dose to the rest of the body, allowing delivery of good uniform dose distributions to the target without significantly irradiating the blocked organ(s). Trade-off surfaces are presented for slices containing a target and one or two critical structures. The method is directly implementable using axial or helical tomotherapy. Implementation for conventional linear accelerators will be more difficult because the number of arcs needed to deliver such treatments can be large, an issue to be explored in future work.

Expected clinical impact of the differences between planned and delivered dose distributions in helical tomotherapy for treating head and neck cancer using helical megavoltage CT images

Helical Tomotherapy (HT) has become increasingly popular over the past few years. However, its clinical efficacy and effectiveness continues to be investigated. Pre-treatment patient repositioning in highly conformal image-guided radiation therapy modalities is a prerequisite for reducing setup uncertainties. A MVCT image set has to be acquired to account for daily changes in the patient's internal anatomy and setup position. Furthermore, a comparison should be performed to the kVCT study used for dosimetric planning, by a registration process which results in repositioning the patient according to specific transitional and rotational shifts. Different image registration techniques may lead to different repositioning of the patient and, as a result, to varying delivered doses. This study aims to investigate the expected effect of patient setup correction using the Hi-Art tomotherapy system by employing radiobiological measures such as the biologically effective uniform dose (BEUD) and the complication-free tumor control probability (P+). In this study, a typical case of lung cancer with metastatic head & neck disease was investigated by developing a Helical Tomotherapy plan. For the Tomotherapy HiArt plan, the dedicated Tomotherapy treatment planning station was used. Three dose distributions (planned and delivered with and without patient setup correction) were compared based on radiobiological measures by using the P+ index and the BEUD concept as the common prescription point of the plans and plotting the tissue response probabilities against the mean target dose for a range of prescription doses. The applied plan evaluation method shows that in this cancer case the planned and delivered dose distributions with and without patient setup correction give a P+ of 81.6%, 80.9% and 72.2%, for a BEUD to the planning target volume (PTV) of 78.0Gy, 77.7Gy and 75.4Gy, respectively. The corresponding tumor control probabilities are 86.3%, 85.1% and 75.1%, whereas the total complication probabilities are 4.64%, 4.20% and 2.89%, respectively. HT can encompass the often large PTV required while minimizing the volume of the organs at risk receiving high dose. However, the effectiveness of a HT treatment plan can be considerably deteriorated if an accurate patient setup system is not available. Taking into account the dose-response relations of the irradiated tumors and normal tissues, a radiobiological treatment plan evaluation can be performed, which may provide a closer association of the delivered treatment with the clinical outcome. In such situations, for effective evaluation and comparison of different treatment plans, traditional dose based evaluation tools can be complemented by the use of P+,BEUD diagrams.

Intensity-modulated whole abdominal radiotherapy after surgery and carboplatin/taxane chemotherapy for advanced ovarian cancer: phase I study

PURPOSE

To assess the feasibility and toxicity of consolidative intensity-modulated whole abdominal radiotherapy (WAR) after surgery and chemotherapy in high-risk patients with advanced ovarian cancer.

METHODS AND MATERIALS

Ten patients with optimally debulked ovarian cancer International Federation of Gynecology and Obstetrics Stage IIIc were treated in a Phase I study with intensity-modulated WAR up to a total dose of 30 Gy in 1.5-Gy fractions as consolidation therapy after adjuvant carboplatin/taxane chemotherapy. Treatment was delivered using intensity-modulated radiotherapy in a step-and-shoot technique (n = 3) or a helical tomotherapy technique (n = 7). The planning target volume included the entire peritoneal cavity and the pelvic and para-aortal node regions. Organs at risk were kidneys, liver, heart, vertebral bodies, and pelvic bones.

RESULTS

Intensity-modulated WAR resulted in an excellent coverage of the planning target volume and an effective sparing of the organs at risk. The treatment was well tolerated, and no severe Grade 4 acute side effects occurred. Common Toxicity Criteria Grade III toxicities were as follows: diarrhea (n = 1), thrombocytopenia (n = 1), and leukopenia (n = 3). Radiotherapy could be completed by all the patients without any toxicity-related interruption. Median follow-up was 23 months, and 4 patients had tumor recurrence (intraperitoneal progression, n = 3; hepatic metastasis, n = 1). Small bowel obstruction caused by adhesions occurred in 3 patients.

CONCLUSIONS

The results of this Phase I study showed for the first time, to our knowledge, the clinical feasibility of intensity-modulated whole abdominal radiotherapy, which could offer a new therapeutic option for consolidation treatment of advanced ovarian carcinoma after adjuvant chemotherapy in selected subgroups of patients. We initiated a Phase II study to further evaluate the toxicity of this intensive multimodal treatment.

An overview of volumetric imaging technologies and their quality assurance for IGRT

Image-guided radiation therapy (IGRT) aims at frequent imaging in the treatment room during a course of radiotherapy, with decisions made on the basis of this information. The concept is not new, but recent developments and clinical implementations of IGRT drastically improved the quality of radiotherapy and broadened its possibilities as well as its indications. In general IGRT solutions can be classified in planar imaging, volumetric imaging using ionising radiation (kV- and MV- based CT) or non-radiographic techniques. This review will focus on volumetric imaging techniques applying ionising radiation with some comments on Quality Assurance (QA) specific for clinical implementation. By far the most important advantage of volumetric IGRT solutions is the ability to visualize soft tissue prior to treatment and defining the spatial relationship between target and organs at risk. A major challenge is imaging during treatment delivery. As some of these IGRT systems consist of peripheral equipment and others present fully integrated solutions, the QA requirements will differ considerably. It should be noted for instance that some systems correct for mechanical instabilities in the image reconstruction process whereas others aim at optimal mechanical stability, and the coincidence of imaging and treatment isocentre needs special attention. Some of the solutions that will be covered in detail are: (a) A dedicated CT-scanner inside the treatment room. (b) Peripheral systems mounted to the gantry of the treatment machine to acquire cone beam volumetric CT data (CBCT). Both kV-based solutions and MV-based solutions using EPIDs will be covered. (c) Integrated systems designed for both IGRT and treatment delivery. This overview will explain some of the technical features and clinical implementations of these technologies as well as providing an insight in the limitations and QA procedures required for each specific solution.

Improving image-guided target localization through deformable registration

PURPOSE

To quantify the improvements in online target localization using kV cone beam CT (CBCT) with deformable registration.

METHODS AND MATERIAL

Twelve patients treated under a 6 fraction liver cancer radiation therapy protocol were imaged in breath hold using kV CBCT at each treatment fraction. The images were imported into the treatment planning software and rigidly registered by fitting the liver, identified on the daily kV CBCT image, into the liver contours, previously drawn on the planning CT. The liver was then manually contoured on each CBCT image. Deformable registration was automatically performed, aligning the CT liver to the liver on each CBCT image using MORFEUS, a biomechanical model based deformable registration algorithm. The tumor, defined on planning CT, was mapped onto the CBCT, through MORFEUS. The center of mass (COM) displacement of the tumor was computed.

RESULTS

The mean (SD) displacement magnitude (absolute value) of the COM following deformable registration was 0.08 (0.07), 0.10 (0.11), and 0.10 (0.17) cm in the left-right (LR), anterior-posterior (AP), and superior-inferior (SI) directions, respectively. The maximum displacement of the COM was 0.34, 0.65, and 0.97 cm in the LR, AP, and SI directions, respectively. Fifteen percent of the treatment fractions had a COM displacement of greater than 0.3 cm and 33% of patients had at least 1 fraction with a displacement of greater than 0.3 cm. The deformable registration, excluding the manual contouring of the liver, was performed in less than 1 minute, on average.

DISCUSSION

Rigid registration of the liver volume between planning CT and verification kV CBCT localizes the tumor to within 0.3 cm for the majority (66%) of patients; however, larger offsets in tumor position can be observed due to liver deformation.

Developments in radiotherapy

A systematic assessment of radiotherapy for cancer was conducted by The Swedish Council on Technology Assessment in Health Care (SBU) in 2001. The assessment included a review of future developments in radiotherapy and an estimate of the potential benefits of improved radiotherapy in Sweden. The conclusions reached from this review can be summarized as: Successively better knowledge is available on dose-response relationships for tumours and normal tissues at different fractionation schedules and treated volumes. Optimization of dose levels and fractionation schedules should improve the treatment outcome. Improved treatment results may be expected with even more optimized fractionation schedules. The radiosensitivity of the tumour is dependent on the availability of free oxygen in the cells. The oxygen effect has been studied for a long time and new knowledge has emerged, but there is still no consensus on the best way to minimize its negative effect in the treatment of hypoxic tumours. Development in imaging techniques is rapid, improving accuracy in outlining targets and organs at risk. This is a prerequisite for advanced treatment planning. More accurate treatment can be obtained using all the computer techniques that are successively made available for calculating dose distributions, controlling the accelerator and multileaf collimator (MLC) and checking patient set-up. Optimized treatment plans can be achieved using inverse dose planning and intensity modulation radiation therapy (IMRT). Optimization algorithms based on biological data from clinical trials could be a part of future dose planning. New genetic markers might be developed that give a measure of the radiation responsiveness of tumours and normal tissue. This could lead to more individualized treatments. New types of radiation sources may be expected: protons, light ions, and improved beams (and compounds) for boron neutron capture therapy (BNCT). Proton accelerators with scanned-beam systems and energy modulation give good dose distribution. The results reported with carbon ions from Japan and Germany are promising. An interesting development is to verify the dose and position for the irradiated volume with PET on line. Safer margins are obtained and the treatment volume can thus be limited. Very large accelerators are needed to accelerate the carbon ions. Still, it should be possible to keep the costs per patient at the same level as those for other types of advanced radiotherapy, since far fewer treatments per patient are needed. It might also be possible to treat new groups of patients. Increased resources are needed to introduce all the currently available techniques. New types of particle accelerators require large investments and a new structure of radiotherapy in Sweden.

Adaptive Radiation Therapy in a Patient with a Massive Nodal Breast Cancer Recurrence

Adaptive radiation therapy (ART) is the next improvement in image-guided radiation therapy (IGRT). ART consists in changing treatment delivery to compensate for changes in patient anatomy or tumor volume. The treatment planning is therefore adapted to the new target volume. By daily imaging, the tumor volume can be assessed and compared with the initial volume. In case of tumor progression or tumor response, a new plan can be obtained to adequately treat the new volume.

We report the use of ART with the Plan Adaptive software of TomoTherapy Inc. in a patient with massive breast cancer recurrence in the axilla. Between the CT simulation and the first day of radiotherapy the axillary lesion progressed. Megavolt CT performed to image-guide the treatment showed impressive growth of the lesion, which went out of the treatment field. By studying the dose distribution on the new anatomy, we found that the planning target volume was substantially undercovered by the prescription dose. Adaptive planning was performed using the anatomical information acquired by the megavolt CT.

Statistical validation of a new helical tomotherapy patient transfer station

The purpose of this work is to evaluate statistically the accuracy of a patient transfer station (PTS, TomoTherapy Inc., Madison, WI) that automatically converts one planning-station-generated treatment plan to another one with a different beam model. In our department we have installed 2 HI*ART tomotherapy systems, and patients often need to be transferred from one tomotherapy unit to the other. Thirty patients who underwent patient transfer between the two systems were evaluated. For each patient, dose differences between his/her original plan and PTS-transferred plan were evaluated by comparing doses at 10 randomly selected positions in his/her CT images. The Pearson indexes were calculated to analyze the relationship of the deviations to other parameters, which include absolute dose levels, sites (targets or normal tissues), dose accuracy of original plans and that of transferred plans. The dose accuracy of a treatment plan was determined by comparing delivered doses at the center of a 30 cm x 30 cm x 12 cm solid water phantom to planned doses at the same position. The calculated dose difference between original and transferred plans was, on average, 0.8% +/- 0.5%; the maximum deviation in absolute values was 1.9% in target volumes and 2.5% in normal organs. The errors generated during PTS-based transferring process were random and did not show correlation with other parameters. The PTS took less than 10 minutes to generate a backup plan that is much less than 2 hours that is approximately needed to create a duplicate plan manually. The results show that a PTS-transferred plan is an acceptable match to the original plan. With a physician's approval, a transferred plan is acceptable for treatment without the necessity of being revalidated in phantom. Thus far, all of our PTS plans have been approved by the treating physician without further optimization.

[Serial tomotherapy vs. MLC-IMRT (multileaf collimator intensity modulated radiotherapy) for simultaneous boost treatment large intracerebral lesions]

INTRODUCTION

Recent data suggest that a radiosurgery boost treatment for up to three brain metastases in addition to whole brain radiotherapy (WBRT) is beneficial. Sequential treatment of multiple metastatic lesions is time-consuming and optimal normal tissue sparing is not trivial for larger metastases when separate plans are created and are only superimposed afterwards. Sequential Tomotherapy (see image I) with noncoplanar arcs and Multi-field IMRT may streamline the process and enable easy simultaneous treatment. We compared plans for 2-3 intracerebral targets calculated with Intensity Modulated Radiotherapy (IMRT) based on treatment with MLC or sequential Tomotherapy using the Peacock-System (see image II). Treatment time was not to exceed 90 min on a linac with standard dose rate. MIMiC plans without treatment-time restrictions were created as a benchmark.

MATERIALS AND METHODS

Calculations are based on a Siemens KD2 linac with a dose rate of 200 MU/min. Step-and-Shoot IMRT is performed with a standard MLC (2 x 29 leaves, 1 cm), serial Tomotherapy with the Multivane-Collimator MIMiC (NOMOS Inc. USA) (see image II). Treatment plans are created with Corvus 5.0. To create plans with good conformity we chose a noncoplanar beam- and arc geometry for each approach (IMRT 4-, MIMiC 5-couch angles). The benchmark MIMiC plans with maximally steep dose gradients had 9 couch angles. For plan comparison reasons, 10 Gy were prescribed to 90% of the PTV. Steepness of dose gradients, homogeneity and conformity were assessed by the following parameters: Volume encompassed by certain isodoses outside the target as well as homogeneity and conformity as indicated by Homogeneity- and Conformity-Index.

RESULTS

Plans without treatment-time restrictions had slightest dose to organ at risk (OAR), normal tissue and least Conformity-index. MIMiC- and MLC-IMRT based plans can be treated within the intended period of 90 min, all plans met the required dose (see Table 2). MLC based plans resulted in higher dose to organs at risk (OAR) (see table 1) and dose to tissue outside the targets (see table 3), as indicated by a higher CI (see image III). The HI was similar for all calculated plans (see image IV).

DISCUSSION

When treatment plans resulting in a similar treatment time were compared, serial Tomotherapy showed minor advantages over MLC based IMRT with regard to conformity, OAR sparing, and steepness of dose gradients. Both methods are inferior to serial Tomotherapy with ideal plan quality disregarding treatment efficiency. Treating multiple metastases in less than 1 h would therefore be possible on a LINAC with high dose rate and bidirectional rotation with minor compromises on gradient steepness.

Dose-volume relationships for acute bowel toxicity in patients treated with pelvic nodal irradiation for prostate cancer

PURPOSE

To find correlation between dose-volume histograms (DVHs) of the intestinal cavity (IC) and moderate-severe acute bowel toxicity in men with prostate cancer treated with pelvic nodal irradiation.

METHODS AND MATERIALS

The study group consisted of 191 patients with localized prostate cancer who underwent whole-pelvis radiotherapy with radical or adjuvant/salvage intent during January 2004 to November 2007. Complete planning/clinical data were available in 175 of these men, 91 of whom were treated with a conventional four-field technique (50.4 Gy, 1.8 Gy/fraction) and 84 of whom were treated with IMRT using conventional Linac (n = 26, 50.4 Gy, 1.8 Gy/fraction) or Helical TomoTherapy (n = 58, 50-54 Gy, 1.8-2 Gy/fraction). The IC outside the planning target volume (PTV) was contoured and the DVH for the first 6 weeks of treatment was recovered in all patients. The correlation between a number of clinical and DVH (V10-V55) variables and toxicity was investigated in univariate and multivariate analyses. The correlation between DVHs for the IC outside the PTV and DVHs for the whole IC was also assessed.

RESULTS

Twenty-two patients experienced toxicity (3/22 in the IMRT/tomotherapy group). Univariate analyses showed a significant correlation between V20-V50 and toxicity (p = 0.0002-0.001), with a higher predictive value observed for V40-V50. Previous prostatectomy (p = 0.066) and abdominal/pelvic surgery (p = 0.12) also correlated with toxicity. Multivariate analysis that included V45, abdominal/pelvic surgery, and prostatectomy showed that the most predictive parameters were V45 (p = 0.002) and abdominal/pelvic surgery (p = 0.05, HR = 2.4)

CONCLUSIONS

Our avoidance IMRT approach drastically reduces the incidence of acute bowel toxicity. V40-V50 of IC and, secondarily, previous abdominal/pelvic surgery were the main predictors of acute bowel toxicity.

Treatment planning to improve delivery accuracy and patient throughput in helical tomotherapy

PURPOSE

To investigate delivery quality assurance (DQA) discrepancies observed for a subset of helical tomotherapy patients.

METHODS AND MATERIALS

Six tomotherapy patient plans were selected for analysis. Three had passing DQA ion chamber (IC) measurements, whereas 3 had measurements deviating from the expected dose by more than 3.0%. All plans used similar parameters, including: 2.5 cm field-width, 15-s gantry period, and pitch values ranging from 0.143 to 0.215. Preliminary analysis suggested discrepancies were associated with plans having predominantly small leaf open times (LOTs). To test this, patients with failing DQA measurements were replanned using an increased pitch of 0.287. New DQA plans were generated and IC measurements performed. Exit fluence data were also collected during DQA delivery for dose reconstruction purposes.

RESULTS

Sinogram analysis showed increases in mean LOTs ranging from 29.8% to 83.1% for the increased pitch replans. IC measurements for these plans showed a reduction in dose discrepancies, bringing all measurements within +/-3.0%. The replans were also more efficient to deliver, resulting in reduced treatment times. Dose reconstruction results were in excellent agreement with IC measurements, illustrating the impact of leaf-timing inaccuracies on plans having predominantly small LOTs.

CONCLUSIONS

The impact of leaf-timing inaccuracies on plans with small mean LOTs can be considerable. These inaccuracies result from deviations in multileaf collimator latency from the linear approximation used by the treatment planning system and can be important for plans having a 15-s gantry period. The ability to reduce this effect while improving delivery efficiency by increasing the pitch is demonstrated.

Megavoltage Computed Tomography Image-based Low-dose Rate Intracavitary Brachytherapy Planning for Cervical Carcinoma

Initial results of megavoltage computed tomography (MVCT) brachytherapy treatment planning are presented, using a commercially available helical tomotherapy treatment unit and standard low dose rate (LDR) brachytherapy applicators used for treatment of cervical carcinoma. The accuracy of MVCT imaging techniques, and dosimetric accuracy of the CT based plans were tested with in-house and commercially-available phantoms. Three dimensional (3D) dose distributions were computed and compared to the two dimensional (2D) dosimetry results. Minimal doses received by the 2 cm3 of bladder and rectum receiving the highest doses (DB2cc and DR2cc, respectively) were computed from dose-volume histograms and compared to the doses computed for the standard ICRU bladder and rectal reference dose points. Phantom test objects in MVCT image sets were localized with sub-millimetric accuracy, and the accuracy of the MVCT-based dose calculation was verified. Fifteen brachytherapy insertions were also analyzed. The ICRU rectal point dose did not differ significantly from DR2cc (p=0.749, mean difference was 24 cGy ± 283 cGy). The ICRU bladder point dose was significantly lower than the DB2cc (p=0.024, mean difference was 291 cGy ± 444 cGy). The median volumes of bladder and rectum receiving at least the corresponding ICRU reference point dose were 6.1 cm3 and 2.0 cm3, respectively. Our initial experience in using MVCT imaging for clinical LDR gynecological brachytherapy indicates that the MVCT images are of sufficient quality for use in 3D, MVCT-based dose planning.

Treatment planning and delivery of IMRT using 6 and 18MV photon beams without flattening filter

In light of the increasing use of intensity modulated radiation therapy (IMRT) in modern radiotherapy practice, the use of a flattening filter may no longer be necessary. Commissioning data have been measured for a Varian 23EX linear accelerator with 6 and 18 MV photon energies without a flattening filter. Measurements collected for the commissioning of the linac included percent depth dose curves and profiles for field sizes ranging from 2 x 2 to 40 x 40 cm(2) as defined by the jaws and multileaf collimator. Machine total scatter factors were measured and calculated. Measurements were used to model the unflattened beams with the Pinnacle(3) treatment planning system. IMRT plans for prostate, lung, brain and head and neck cancer cases were generated using the flattening filter and flattening filter-free beams. From our results, no difference in the quality of the treatment plans between the flat and unflattened photon beams was noted. There was however a significant decrease in the number of monitor units required for unflattened beam treatment plans due to the increase in linac output-approximately two times and four times higher for the 6 and 18 MV, respectively.

Total marrow irradiation with helical tomotherapy for bone marrow transplantation of multiple myeloma: first experience in Asia

Three Asian patients with plasma cell myeloma stage IIIa with IgG predominant were selected for autologous hematopoietic cell transplantation (HSCT). Total marrow irradiation (TMI) tomotherapy planned with melphalan 140 mg/m2 as a preconditioning regimen of HSCT. Two image sets of computed tomography (CT) were scanned with 2.5 mm and 5 mm for the upper and lower part of the plan, respectively. The junction was determined and marked at 15 cm above knee on both thighs for upper and lower part of the plan. The clinical target volume (CTV) included the entire skeletal system. The planning target volume (PTV) was generated with with 0.8 cm for CTV(extremities) and with 0.5 cm margin for all other bones of CTV. A total dose of 800 cGy (200 cGy/fraction) was delivered to the PTV. Update to presentation, all of three patients post transplant without evidence of active disease were noted. During TMI treatment, one with grade 1 vomiting, two with grade 1 nausea, one with grade 1 mucositis, and three with grade 1 anorexia were noted. Toxicity of treatment was scored according to the Common Terminology Criteria for Adverse Events v3.0 (CTCAE v3.0). The average for upper part versus lower part of PTV (Bone marrow) of CI and H-index were 1.5 and 1.4 versus 1.2 and 1.2, respectively. The dose reduction of TMI tomotherapy to various OARs of head, chest, and abdomen relative to TBI varied from 31% to 74%, 21% to 51%, and 46% to 63%, respectively. The maximum average value of registration for upper torso versus lower extremities in different translation directions were 5.1 mm versus 4.1 mm for pretreatment and 1.5 mm versus 0.7 mm for post-treatment, respectively. The average treatment time for the upper versus lower part in beam-on time, setup time, and MVCT registration time took roughly 49.9, 23.3, and 11.7 min versus 11.5, 10.0, and 7.3 min, respectively. The margin of PTV could be less than 1 cm under good fixation and close position confirmation with MVCT. Antiemetics should be prescribed in the whole course of TMI for emesis prevention. TMI technique replaced TBI technique with 8 Gy as conditioning regiment for multiple myeloma could be acceptable for the Asian and the outcomes were feasible for the Asian.